Literature DB >> 12089321

Population genomics of drug resistance in Candida albicans.

Leah E Cowen1, André Nantel, Malcolm S Whiteway, David Y Thomas, Daniel C Tessier, Linda M Kohn, James B Anderson.   

Abstract

We followed adaptation in experimental microbial populations to inhibitory concentrations of an antimicrobial drug. The evolution of drug resistance was accompanied in all cases by changes in gene expression that persisted in the absence of the drug; the new patterns of gene expression were constitutive. The changes in gene expression occurred in four replicate populations of the pathogenic fungus Candida albicans during 330 generations of evolution in the presence of the antifungal drug fluconazole. Genome-wide expression profiling of over 5,000 ORFs identified 301 whose expression was significantly modulated. Cluster analysis identified three distinct patterns of gene expression underlying adaptation to the drug. One pattern was unique to one population and included up-regulation of the multidrug ATP-binding cassette transporter gene, CDR2. A second pattern occurred at a late stage of adaptation in three populations; for two of these populations profiled earlier in their evolution, a different pattern was observed at an early stage of adaptation. The succession of early- and late-stage patterns of gene expression, both of which include up-regulation of the multidrug major facilitator transporter gene, MDR1, must represent a common program of adaptation to this antifungal drug. The three patterns of gene expression were also identified in fluconazole-resistant clinical isolates, providing further evidence that these patterns represent common programs of adaptation to fluconazole.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12089321      PMCID: PMC123132          DOI: 10.1073/pnas.102291099

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Multilocus genotypes and DNA fingerprints Do not predict variation in azole resistance among clinical isolates of Candida albicans.

Authors:  L E Cowen; C Sirjusingh; R C Summerbell; S Walmsley; S Richardson; L M Kohn; J B Anderson
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

2.  Multilocus genotyping indicates that the ability to invade the bloodstream is widespread among Candida albicans isolates.

Authors:  L N Luu; L E Cowen; C Sirjusingh; L M Kohn; J B Anderson
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

Review 3.  Principles for the buffering of genetic variation.

Authors:  J L Hartman; B Garvik; L Hartwell
Journal:  Science       Date:  2001-02-09       Impact factor: 47.728

4.  Functional discovery via a compendium of expression profiles.

Authors:  T R Hughes; M J Marton; A R Jones; C J Roberts; R Stoughton; C D Armour; H A Bennett; E Coffey; H Dai; Y D He; M J Kidd; A M King; M R Meyer; D Slade; P Y Lum; S B Stepaniants; D D Shoemaker; D Gachotte; K Chakraburtty; J Simon; M Bard; S H Friend
Journal:  Cell       Date:  2000-07-07       Impact factor: 41.582

5.  Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

Authors:  Dominique Sanglard; Françoise Ischer; Michel Monod; Jacques Bille
Journal:  Microbiology (Reading)       Date:  1997-02       Impact factor: 2.777

6.  The epidemiology of invasive mycoses--narrowing the gap.

Authors:  M A Pfaller
Journal:  Clin Infect Dis       Date:  1998-11       Impact factor: 9.079

Review 7.  Population biology, evolution, and infectious disease: convergence and synthesis.

Authors:  B R Levin; M Lipsitch; S Bonhoeffer
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

Review 8.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

9.  Genome microarray analysis of transcriptional activation in multidrug resistance yeast mutants.

Authors:  J DeRisi; B van den Hazel; P Marc; E Balzi; P Brown; C Jacq; A Goffeau
Journal:  FEBS Lett       Date:  2000-03-24       Impact factor: 4.124

10.  Evolution of drug resistance in experimental populations of Candida albicans.

Authors:  L E Cowen; D Sanglard; D Calabrese; C Sirjusingh; J B Anderson; L M Kohn
Journal:  J Bacteriol       Date:  2000-03       Impact factor: 3.490

View more
  51 in total

Review 1.  Molecular genetic and genomic approaches to the study of medically important fungi.

Authors:  P T Magee; Cheryl Gale; Judith Berman; Dana Davis
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

2.  Transcription profiling of Candida albicans cells undergoing the yeast-to-hyphal transition.

Authors:  André Nantel; Daniel Dignard; Catherine Bachewich; Doreen Harcus; Anne Marcil; Anne-Pascale Bouin; Christoph W Sensen; Hervé Hogues; Marco van het Hoog; Paul Gordon; Tracey Rigby; François Benoit; Daniel C Tessier; David Y Thomas; Malcolm Whiteway
Journal:  Mol Biol Cell       Date:  2002-10       Impact factor: 4.138

3.  Proteomic analysis of azole resistance in Candida albicans clinical isolates.

Authors:  Massoumeh Z Hooshdaran; Katherine S Barker; George M Hilliard; Harald Kusch; Joachim Morschhäuser; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

4.  Non-glucan attached proteins of Candida albicans biofilm formed on various surfaces.

Authors:  Govindsamy Vediyappan; W Lajean Chaffin
Journal:  Mycopathologia       Date:  2006-01       Impact factor: 2.574

5.  Inhibition of efflux transporter-mediated fungicide resistance in Pyrenophora tritici-repentis by a derivative of 4'-hydroxyflavone and enhancement of fungicide activity.

Authors:  Sven Reimann; Holger B Deising
Journal:  Appl Environ Microbiol       Date:  2005-06       Impact factor: 4.792

6.  In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling.

Authors:  D Andes; A Lepak; J Nett; L Lincoln; K Marchillo
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 7.  Will resistance in fungi emerge on a scale similar to that seen in bacteria?

Authors:  H Hof
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-19       Impact factor: 3.267

8.  A genome-wide steroid response study of the major human fungal pathogen Candida albicans.

Authors:  Dibyendu Banerjee; Nuria Martin; Soumyadeep Nandi; Sudhanshu Shukla; Angel Dominguez; Gauranga Mukhopadhyay; Rajendra Prasad
Journal:  Mycopathologia       Date:  2007-06-16       Impact factor: 2.574

9.  Multidrug-resistant transporter mdr1p-mediated uptake of a novel antifungal compound.

Authors:  Nuo Sun; Dongmei Li; William Fonzi; Xin Li; Lixin Zhang; Richard Calderone
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

10.  Candida albicans response regulator gene SSK1 regulates a subset of genes whose functions are associated with cell wall biosynthesis and adaptation to oxidative stress.

Authors:  Neeraj Chauhan; Diane Inglis; Elvira Roman; Jesus Pla; Dongmei Li; Jose A Calera; Richard Calderone
Journal:  Eukaryot Cell       Date:  2003-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.